Indoco Remedies has announced the launch of Brinzolamide Ophthalmic Suspension 1% in the United States, the first
generic version of AZOPT by Teva Pharmaceuticals. The product is developed and manufactured by Indoco Remedies Ltd. for
TEVA at its facility in Goa.
The ANDA approved by the US Food and Drug Administration for Brinzolamide Ophthalmic Suspension 1%, is used to treat
high pressure inside the eye due to ocular hypertension and open-angle glaucoma.
Brinzolamide Ophthalmic Suspension 1% works by decreasing the amount of fluid within the eye.
The US market size of this product is $184 million, according to IQVIA data as of December, 2020.
Commenting on this achievement, Aditi Kare Panandikar, Managing Director - Indoco Remedies Ltd. said, “This first-to-market
generic version of AZOPT® (Brinzolamide Ophthalmic Suspension 1%, developed by Indoco) in the U.S. brings in an enormous opportunity
to Indoco to serve the patients with a generic option. It also provides us immense satisfaction to be part of the journey in developing
and securing approval from the US regulators for such Complex Generic products (ophthalmic suspensions), ensuring access to affordable and
quality medicines"
Panandikar also added, “Indoco is vertically integrated for Brinzolamide API (manufactured at Patalganga site), which gives an
edge to ensure continuity in commercial supplies.”
On Tuesday, at around 1:35 PM, Indoco Remedies was trading at Rs289.80 per piece up by Rs13.20 or 4.77% on Sensex.
|